- 55,000 vials of peptides will be produced from this production suite and are pre-sold
- Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September
MEQUON, Wis., Aug. 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) (the "Company") today announced that the first of four planned manufacturing suites at its LyoGenesis Manufacturing facility is now producing pharma-grade peptides, putting the Company on track to begin fulfilling Vector's existing customer orders for nine peptides this month.
Outside of the GLP-1s, Vector will focus production on top-selling peptides and complementary compounds such as Sermorelin, BPC-157, NAD, TB-500, PT-141, KPV, Semax, Epitalon, and MOTS-c to meet growing demand for peptides in the USA. After accounting for LyoGenesis Manufacturing's production costs, Vector expects to retain a margin of approximately 80% on each sale, reflecting the premium that pharma-grade peptides command over lower-cost, research-grade material that lacks comparable manufacturing, quality, and regulatory rigor.
The milestone follows an extensive qualification process required to bring each suite into full cGMP, FDA, and ISO compliance, including:
- Successful completion of process validation batches confirming consistent yield, purity, and potency
- Calibration and qualification of all manufacturing equipment
- Validation of air quality and air pressure in each Class 5 cleanroom
- Development and validation of cleaning protocols for every room and piece of equipment
- Process-control SOPs governing cleanroom access and equipment operation
- Development of production, raw-material, and finished-product specifications
- Completion of staff training on all qualified equipment and procedures
"We projected we would begin producing revenue from the Mequon facility, and we met our timeline because of the effort our entire team put in," said Tommy Thompson, Chairman of Vector Science & Therapeutics. "This is a significant milestone that allows us to begin to meet the commitments we've made to our customers."
"Every suite goes through the same rigorous qualification process before it can produce a single vial," said Bill Jackson, Chief Executive Officer of Vector Science & Therapeutics. "That discipline is what allows us to stand behind the quality of what leaves this facility, and it's what our partners and their patients are counting on."
Scaling Through September
The first suite is currently capable of producing approximately 55,000 vials per month, which has been presold. The three remaining LyoGenesis Manufacturing suites are expected to come online in the latter half of September 2026, each with a substantially larger production profile than the first suite, together giving the Company combined capacity to produce up to 800,000 vials of peptides per month. As additional capacity comes on stream, the Company expects to scale production to approximately 200,000 vials per month within the next three months. One major customer has signaled it expects to commit to purchasing 200,000 vials per month within three months.
Independent Quality Verification
All peptides produced at LyoGenesis Manufacturing undergo validated testing performed by Verlytix, LyoGenesis Manufacturing's related-company quality and analytical testing affiliate, confirming sterility, purity, potency, endotoxin levels, and water content.
About Vector Science & Therapeutics Corp.
Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing drug delivery technology and peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. The Company's product and intellectual property portfolio is focused on advanced transdermal delivery, precision catheter systems, localized pain management, pancreatic oncology, and smart wound care.
Vector is headquartered in Mequon, Wisconsin. For more information, visit https://vectorscience.co/.
All peptide candidates referenced are development-stage and investigational. They have not been approved for any indication.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding the Company's production capacity and timeline for bringing additional manufacturing suites online, anticipated customer demand and order fulfillment, anticipated profit margins, and the scaling of the Company's peptide manufacturing operations. Forward-looking information is based on management's current expectations and assumptions and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake any obligation to update forward-looking information except as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vector-science--therapeutics-tsxv-pain-begins-peptide-production-as-first-suite-at-lyogenesis-manufacturing-comes-online-302857980.html
SOURCE Vector Sciences & Therapeutics
